Dr. Samarpan Majumder, Ph.D., is an Associate Professor in the Department of Genetics at LSU Health Sciences Center, New Orleans; where he conducts translational oncology research focused on pancreatic ductal adenocarcinoma (PDAC) and breast cancer. With over 27 years of experience spanning academia and biotechnology, Dr. Majumder held senior scientist positions, including Director of Preclinical Development at Vascular Pharmaceuticals and leadership in diagnostic kit development for blood clotting disorders at Novametics. His current research integrates molecular mechanisms with therapeutic innovation. In PDAC, he has demonstrated the dual antithrombotic and antitumor effects of Protein S, a natural anticoagulant, showing that exogenous Protein S inhibits tumor progression and immune modulation in preclinical models. In breast cancer, his work addresses treatment resistance: he has established the efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in overcoming endocrine resistance in ER-positive disease (often in combination with standard therapies like fulvestrant) and explores gut microbiome to enhance immunotherapy efficacy in triple-negative breast cancer, particularly in obesity contexts. Dr. Majumder is an expert in preclinical cancer models, tumor microenvironment, cancer stem cells, exosomes, and immunotherapy. His research bridges basic science and clinical application to develop targeted therapies for aggressive malignancies.